About Healius (ASX: HLS)
Healius Limited is an Australian healthcare company focused on the provision of medical laboratory and pathology services across Australia, operating a network of medical laboratories and patient collection centres that serve both clinical and diagnostic needs.
The company delivers its services through a broad portfolio of brands, including Laverty Pathology, Dorevitch Pathology, QML Pathology, Western Diagnostic Pathology, Genomic Diagnostic, Vetnostics Pathology, TML Pathology, Abbott Pathology, IQ Pathology, Kossard, Gastrolab, and Agilex Biolabs. Formerly known as Primary Health Care Limited, the company adopted the Healius name in December 2018. Incorporated in 1994, Healius is headquartered in Sydney, Australia.
MFAM Research
- [BUY] Healius (ASX:HLS) is an Undervalued Healthcare Services Provider in a Growing IndustryOctober 8, 2020Today we’ll look at why we like Healius shares (ASX:HLS) and we’ll give you a rundown of our HLS share price forecast. Healius is a healthcare services provider with three main businesses – pathology, imaging and medical centres. With an aging population and a growing pathology industry, Healius is well-positioned to take advantage of the […]
Latest Announcements
- Healius (ASX: HLS) – Healius FY26 Results Presentation SlidesAugust 19, 2026Healius Limited’s full-year results for FY26 demonstrate solid operational execution in a challenging environment, with underlying EBITDA growing 8.1 percent to $258.6 million despite modest revenue growth of just 2.1 percent to $1,373.2 million. The divergence between revenue and earnings growth reflects the company’s focus on margin improvement through revenue mix optimization and disciplined cost […]
- Healius (ASX: HLS) – Healius Announces FY2026 Financial ResultsAugust 19, 2026Healius Limited delivered a significant earnings upgrade in FY 2026, with underlying earnings before interest and tax surging 76.6% to $30.2 million, substantially outperforming the 8.1% growth in EBITDA to $258.6 million. This disproportionate EBIT expansion reveals the real story: disciplined cost management and operational leverage are beginning to materialise after years of sector headwinds. […]
- Healius (ASX: HLS) – Healius Files FY26 Preliminary Final ReportAugust 19, 2026Healius reported a basic loss per share of 57.2 cents for the year ended 30 June 2026, compared to 20.8 cents in the prior year, marking a significant deterioration in headline results. However, the underlying loss per share improved to 1.8 cents from 3.4 cents, indicating that core operational performance has moved in the right […]
- Healius (ASX: HLS) – Transitions pathology arrangements with Ramsay 3June 26, 2026Healius Limited has secured renewal of its pathology service arrangements with Ramsay Health Care subsidiaries, with the agreement expected to generate approximately $45 million in annual revenue under the initial contract terms. The transition takes effect on 1 July 2026 and consolidates Healius’ existing pathology leases and service arrangements across thirteen Ramsay-operated hospitals into a […]
- Healius (ASX: HLS) – FY26 Trading Update and Strategic ReviewMay 13, 2026Healius Limited has provided a FY26 trading update that reveals a company navigating conflicting pressures. The company expects underlying EBITDA between 259 million and 264 million dollars, with EBIT guidance of 30 million to 35 million dollars. Concurrent with these financial projections, Healius has engaged UBS Securities to explore a sale of Agilex Biolabs, its […]
Financial Summary
Price History
Related Stocks
| Same Industry — Healthcare | Same Sub-Industry — Diagnostics & Research |
|---|---|